Advanced AI and ML frameworks for transforming drug discovery and optimization: With innovative insights in polypharmacology, drug repurposing, combination therapy and nanomedicine

被引:14
作者
Ambreen, Subiya [1 ]
Umar, Mohammad [1 ]
Noor, Aaisha [1 ]
Jain, Himangini [1 ]
Ali, Ruhi [1 ]
机构
[1] DPSRU, Delhi Inst Pharmaceut Sci & Res DIPSAR, Dept Pharmaceut Chem, New Delhi 110017, India
关键词
PROTEIN INTERACTION PREDICTION; LARGE-SCALE PREDICTION; X RECEPTOR ACTIVATORS; DEEP NEURAL-NETWORKS; ARTIFICIAL-INTELLIGENCE; PHYSICAL-PROPERTIES; DATABASE; DESIGN; FUTURE; QSAR;
D O I
10.1016/j.ejmech.2024.117164
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Artificial Intelligence (AI) and Machine Learning (ML) are transforming drug discovery by overcoming traditional challenges like high costs, time-consuming, and frequent failures. AI-driven approaches streamline key phases, including target identification, lead optimization, de novo drug design, and drug repurposing. Frameworks such as deep neural networks (DNNs), convolutional neural networks (CNNs), and deep reinforcement learning (DRL) models have shown promise in identifying drug targets, optimizing delivery systems, and accelerating drug repurposing. Generative adversarial networks (GANs) and variational autoencoders (VAEs) aid de novo drug design by creating novel drug-like compounds with desired properties. Case studies, such as DDR1 kinase inhibitors designed using generative models and CDK20 inhibitors developed via structure-based methods, highlight AI's ability to produce highly specific therapeutics. Models like SNF-CVAE and DeepDR further advance drug repurposing by uncovering new therapeutic applications for existing drugs. Advanced ML algorithms enhance precision in predicting drug efficacy, toxicity, and ADME-Tox properties, reducing development costs and improving drug-target interactions. AI also supports polypharmacology by optimizing multi-target drug interactions and enhances combination therapy through predictions of drug synergies and antagonisms. In nanomedicine, AI models like CURATE.AI and the Hartung algorithm optimize personalized treatments by predicting toxicological risks and real-time dosing adjustments with high accuracy. Despite its potential, challenges like data quality, model interpretability, and ethical concerns must be addressed. High-quality datasets, transparent models, and unbiased algorithms are essential for reliable AI applications. As AI continues to evolve, it is poised to revolutionize drug discovery and personalized medicine, advancing therapeutic development and patient care.
引用
收藏
页数:22
相关论文
共 303 条
[61]   A Review on Generative Adversarial Networks: Algorithms, Theory, and Applications [J].
Gui, Jie ;
Sun, Zhenan ;
Wen, Yonggang ;
Tao, Dacheng ;
Ye, Jieping .
IEEE TRANSACTIONS ON KNOWLEDGE AND DATA ENGINEERING, 2023, 35 (04) :3313-3332
[62]   An application of machine learning to haematological diagnosis [J].
Guncar, Gregor ;
Kukar, Matjaz ;
Notar, Mateja ;
Brvar, Miran ;
Cernelc, Peter ;
Notar, Manca ;
Notar, Marko .
SCIENTIFIC REPORTS, 2018, 8
[63]   Using support vector machine combined with auto covariance to predict proteinprotein interactions from protein sequences [J].
Guo, Yanzhi ;
Yu, Lezheng ;
Wen, Zhining ;
Li, Menglong .
NUCLEIC ACIDS RESEARCH, 2008, 36 (09) :3025-3030
[64]   Generative Recurrent Networks for De Novo Drug Design [J].
Gupta, Anvita ;
Mueller, Alex T. ;
Huisman, Berend J. H. ;
Fuchs, Jens A. ;
Schneider, Petra ;
Schneider, Gisbert .
MOLECULAR INFORMATICS, 2018, 37 (1-2)
[65]   Artificial intelligence to deep learning: machine intelligence approach for drug discovery [J].
Gupta, Rohan ;
Srivastava, Devesh ;
Sahu, Mehar ;
Tiwari, Swati ;
Ambasta, Rashmi K. ;
Kumar, Pravir .
MOLECULAR DIVERSITY, 2021, 25 (03) :1315-1360
[66]   Deep learning algorithms applied to computational chemistry [J].
Guzman-Pando, Abimael ;
Ramirez-Alonso, Graciela ;
Arzate-Quintana, Carlos ;
Camarillo-Cisneros, Javier .
MOLECULAR DIVERSITY, 2024, 28 (04) :2375-2410
[67]   Artificial intelligence in medicine [J].
Hamet, Pavel ;
Tremblay, Johanne .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2017, 69 :S36-S40
[68]  
Hartung T, 2010, ALTEX-ALTERN ANIM EX, V27, P87
[69]  
Hasan B., 2021, J. Soft Comput. Data Min, V2, P20, DOI DOI 10.30880/JSCDM.2021.02.01.003
[70]   Predicting protein-protein interactions through sequence-based deep learning [J].
Hashemifar, Somaye ;
Neyshabur, Behnam ;
Khan, Aly A. ;
Xu, Jinbo .
BIOINFORMATICS, 2018, 34 (17) :802-810